Annual Shareholders Equity
$30.05 M
-$30.92 M-50.71%
December 31, 2023
Summary
- As of February 7, 2025, ONCT annual stockholders equity is $30.05 million, with the most recent change of -$30.92 million (-50.71%) on December 31, 2023.
- During the last 3 years, ONCT annual shareholders equity has fallen by -$82.90 million (-73.39%).
- ONCT annual shareholders equity is now -73.39% below its all-time high of $112.95 million, reached on December 31, 2020.
Performance
ONCT Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Shareholders Equity
$9.15 M
-$6.61 M-41.93%
September 30, 2024
Summary
- As of February 7, 2025, ONCT quarterly stockholders equity is $9.15 million, with the most recent change of -$6.61 million (-41.93%) on September 30, 2024.
- Over the past year, ONCT quarterly shareholders equity has dropped by -$13.78 million (-60.10%).
- ONCT quarterly shareholders equity is now -91.90% below its all-time high of $112.95 million, reached on December 31, 2020.
Performance
ONCT Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
ONCT Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -50.7% | -60.1% |
| 3 y3 years | -73.4% | -82.6% |
| 5 y5 years | +15.1% | -82.6% |
ONCT Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -65.9% | at low | -89.6% | at low |
| 5 y | 5-year | -73.4% | +110.0% | -91.9% | at low |
| alltime | all time | -73.4% | +120.0% | -91.9% | +106.1% |
Oncternal Therapeutics Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $9.15 M(-41.9%) |
| Jun 2024 | - | $15.75 M(-31.3%) |
| Mar 2024 | - | $22.93 M(-23.7%) |
| Dec 2023 | $30.05 M(-50.7%) | $30.05 M(-18.8%) |
| Sep 2023 | - | $37.00 M(-18.1%) |
| Jun 2023 | - | $45.18 M(-13.9%) |
| Mar 2023 | - | $52.49 M(-13.9%) |
| Dec 2022 | $60.97 M(-30.8%) | $60.97 M(-11.1%) |
| Sep 2022 | - | $68.54 M(-7.4%) |
| Jun 2022 | - | $74.00 M(-7.7%) |
| Mar 2022 | - | $80.19 M(-9.0%) |
| Dec 2021 | $88.12 M(-22.0%) | $88.12 M(-6.7%) |
| Sep 2021 | - | $94.48 M(-7.8%) |
| Jun 2021 | - | $102.52 M(-5.3%) |
| Mar 2021 | - | $108.30 M(-4.1%) |
| Dec 2020 | $112.95 M(+689.2%) | $112.95 M(+619.4%) |
| Sep 2020 | - | $15.70 M(+63.6%) |
| Jun 2020 | - | $9.60 M(-7.7%) |
| Mar 2020 | - | $10.39 M(-27.4%) |
| Dec 2019 | $14.31 M(-45.2%) | $14.31 M(-21.1%) |
| Sep 2019 | - | $18.15 M(-20.9%) |
| Jun 2019 | - | $22.94 M(+10.2%) |
| Mar 2019 | - | $20.82 M(-20.3%) |
| Dec 2018 | $26.11 M(-31.8%) | $26.11 M(-15.7%) |
| Sep 2018 | - | $30.96 M(-22.3%) |
| Jun 2018 | - | $39.84 M(+61.0%) |
| Mar 2018 | - | $24.75 M(-35.3%) |
| Dec 2017 | $38.26 M(+92.4%) | $38.26 M(-17.8%) |
| Sep 2017 | - | $46.57 M(+449.0%) |
| Jun 2017 | - | $8.48 M(-40.2%) |
| Mar 2017 | - | $14.19 M(-28.7%) |
| Dec 2016 | $19.89 M(+970.0%) | $19.89 M(+60.6%) |
| Sep 2016 | - | $12.38 M(-32.9%) |
| Jun 2016 | - | $18.45 M(-22.1%) |
| Mar 2016 | - | $23.68 M(+1174.1%) |
| Dec 2015 | $1.86 M(-89.6%) | $1.86 M(-56.9%) |
| Sep 2015 | - | $4.31 M(-113.8%) |
| Jun 2015 | - | -$31.31 M(-297.0%) |
| Mar 2015 | - | $15.89 M(-10.8%) |
| Dec 2014 | $17.83 M(+66.9%) | $17.83 M(+67.9%) |
| Sep 2014 | - | $10.62 M(-30.5%) |
| Jun 2014 | - | $15.29 M(-39.1%) |
| Mar 2014 | - | $25.09 M(+134.8%) |
| Dec 2013 | $10.68 M | $10.68 M(-36.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $16.94 M(-31.6%) |
| Jun 2013 | - | $24.76 M(-31.3%) |
| Mar 2013 | - | $36.06 M(-24.4%) |
| Dec 2012 | $47.70 M(-33.6%) | $47.70 M(-20.4%) |
| Sep 2012 | - | $59.91 M(+15.9%) |
| Jun 2012 | - | $51.69 M(-16.3%) |
| Mar 2012 | - | $61.77 M(-14.1%) |
| Dec 2011 | $71.87 M(+38.9%) | $71.87 M(-11.8%) |
| Sep 2011 | - | $81.47 M(-9.2%) |
| Jun 2011 | - | $89.71 M(+78.1%) |
| Mar 2011 | - | $50.38 M(-2.6%) |
| Dec 2010 | $51.73 M(-691.2%) | $51.73 M(+187.6%) |
| Sep 2010 | - | $17.98 M(-29.3%) |
| Jun 2010 | - | $25.44 M(-31.8%) |
| Mar 2010 | - | $37.30 M(-526.3%) |
| Dec 2009 | -$8.75 M(-127.3%) | -$8.75 M(<-9900.0%) |
| Sep 2009 | - | $24.00 K(-99.8%) |
| Jun 2009 | - | $11.70 M(-46.4%) |
| Mar 2009 | - | $21.84 M(-31.8%) |
| Dec 2008 | $32.02 M(-59.4%) | $32.02 M(-28.2%) |
| Sep 2008 | - | $44.58 M(-19.1%) |
| Jun 2008 | - | $55.12 M(-17.8%) |
| Mar 2008 | - | $67.09 M(-15.0%) |
| Dec 2007 | $78.92 M(-18.7%) | $78.92 M(+9.8%) |
| Sep 2007 | - | $71.87 M(-11.4%) |
| Jun 2007 | - | $81.16 M(-9.6%) |
| Mar 2007 | - | $89.82 M(-7.4%) |
| Dec 2006 | $97.05 M(+31.9%) | $97.05 M(+121.1%) |
| Sep 2006 | - | $43.90 M(-19.3%) |
| Jun 2006 | - | $54.43 M(-15.0%) |
| Mar 2006 | - | $64.00 M(-13.0%) |
| Dec 2005 | $73.58 M(+15.1%) | $73.58 M(+107.2%) |
| Sep 2005 | - | $35.51 M(-21.6%) |
| Jun 2005 | - | $45.27 M(-17.8%) |
| Mar 2005 | - | $55.10 M(-13.8%) |
| Dec 2004 | $63.91 M(-142.5%) | $63.91 M(-9.5%) |
| Sep 2004 | - | $70.58 M(-6.5%) |
| Jun 2004 | - | $75.52 M(-5.4%) |
| Mar 2004 | - | $79.86 M(-153.2%) |
| Dec 2003 | -$150.23 M(+171.6%) | -$150.23 M |
| Dec 2002 | -$55.31 M(+62.3%) | - |
| Dec 2001 | -$34.08 M(+35.4%) | - |
| Dec 2000 | -$25.16 M(<-9900.0%) | - |
| Dec 1999 | $21.00 K | - |
FAQ
- What is Oncternal Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual shareholders equity year-on-year change?
- What is Oncternal Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly shareholders equity year-on-year change?
What is Oncternal Therapeutics annual stockholders equity?
The current annual shareholders equity of ONCT is $30.05 M
What is the all time high annual shareholders equity for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual stockholders equity is $112.95 M
What is Oncternal Therapeutics annual shareholders equity year-on-year change?
Over the past year, ONCT annual stockholders equity has changed by -$30.92 M (-50.71%)
What is Oncternal Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of ONCT is $9.15 M
What is the all time high quarterly shareholders equity for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly stockholders equity is $112.95 M
What is Oncternal Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, ONCT quarterly stockholders equity has changed by -$13.78 M (-60.10%)